Not independent
Tenure on this board
10.2 yrs
Meeting calendar
ANGO · Annual meeting · Monday, November 10, 2025
Angiodynamics Inc
2 nominees · 3 ballot items.
The proxy requests votes on three matters: election of two Class I directors, ratification of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for fiscal year ending May 31, 2026, and an advisory Say-on-Pay vote on the compensation of AngioDynamics’ named executive officers.
Market cap
$541M
1Y TSR
+16.8%
Board grade
C
Record date
Sep 18, 2025
Filing
DEF 14A
Meeting concluded · Nov 10, 2025
Follow how the vote landed and what changed on Angiodynamics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElection of two Class I directors to serve three-year terms.
- 2
Ratification of the appointment of our independent registered public accounting firm for the fiscal year ending May 31, 2026
ManagementBoard: FORRatify Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2026.
- 3
Advisory vote on the compensation of our named executive officers
ManagementBoard: FORAdvisory (Say-on-Pay) vote on the compensation of AngioDynamics’ named executive officers as disclosed in this proxy statement.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
6.7 yrs
Also a director at
Avita Medical Inc (RCEL)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P.Activist | 7.7% | 3,181,829 | $36M |
| 2 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 5.8% | 2,414,461 | $27M |
| 3 | Broadfin Holdings LLC | 5.0% | 2,069,333 | $24M |
| 4 | ARMISTICE CAPITAL, LLC | 4.5% | 1,869,000 | $21M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 1,726,820 | $20M |
| 6 | BlackRock, Inc. | 3.9% | 1,629,629 | $19M |
| 7 | ROYCE ASSOCIATES LP | 3.7% | 1,528,951 | $17M |
| 8 | BlackRock, Inc. | 3.5% | 1,449,733 | $16M |
| 9 | WEBER CAPITAL MANAGEMENT LLC /ADV | 3.3% | 1,373,149 | $16M |
| 10 | STATE STREET CORP | 3.2% | 1,333,858 | $15M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Angiodynamics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Reference
Frequently asked questions
- When is the Angiodynamics Inc 2025 annual meeting?
- Angiodynamics Inc (ANGO) holds its 2025 annual shareholder meeting on Monday, November 10, 2025.
- What is the record date for the Angiodynamics Inc 2025 meeting?
- The record date for the Angiodynamics Inc 2025 meeting is Thursday, September 18, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Angiodynamics Inc's 2025 meeting?
- The board is presenting 2 director nominees at the Angiodynamics Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Angiodynamics Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Angiodynamics Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.